They compared the organoids’ response to HER2 pathway inhibitors and poly ADP-ribose polymerase(PARP) inhibitors, finding that HER2-overexpressing organoids were sensitive to anti-HER2 targeted drugs and that BRCAI-mutated breast cancer organoids were sensitive to PARP inhibitors, suggesting that breast cancer organoids can be used to predict the drug response in clinical breast cancer patients (30). Here, ERBB2 is linked to breast carcinoma.